CD274 and non-small cell lung carcinoma: Furthermore, based on the objective response rate, PD-L1 high NSCLC patients gain more benefits than PD-L1 low patients in response to treatment with cemiplimab in combination with chemotherapy (EMPOWER-Lung 3; PD-L1 screen: 22C3 pharmDx assay) [13].